Virtual meeting
Via Zoom
Description
This training is designed to provide foundational knowledge and skills in initiating buprenorphine treatment for opioid use disorder in the outpatient setting in the context of the widespread presence of illicitly manufactured fentanyl. We explore how the potency and prevalence of fentanyl complicates the initiation phase of buprenorphine treatment, leading to potential clinical challenges such as precipitated withdrawal. We suggest participating in the next training in the series, Buprenorphine 201, upon completing Buprenorphine 101.
Intended audience
Medical providers (physicians, advanced practice providers), nurses, and other clinical team members that support medical management of opioid use disorder.
Speakers
Megan (Meg) Hudson, MSN, PMHNP-BC (she/her)
Meg is a clinical nurse educator with Boston Medical Center's (BMC) Grayken Center for Addiction Training and Technical Assistance and a psychiatric mental health nurse practitioner at Boston Medical Center. Prior to obtaining her MSN, she worked as a nurse care manager in the Stimulant Treatment and Recovery Clinic (START) clinic, integrating harm reduction, infectious disease treatment, medical addiction groups, and co-management of stimulant use disorders and mental health conditions. Her clinical expertise includes harm reduction, low barrier treatment, complex care management, early identification and management of acute and persistent stimulant-induced psychosis. She earned both her BSN and MSN from Regis College.
Annie Potter, MSN, MPH, FNP-C, CARN-AP (she/her)
Annie is a clinical nurse educator for Boston Medical Center's (BMC) Grayken Center for Addiction Training and Technical Assistance, a Nurse Practitioner in General Internal Medicine at BMC, and an assistant professor of medicine at Boston University Chobanian & Avedisian School of Medicine. Annie earned a master’s in nursing and public health from Johns Hopkins University and is certified as a Certified Addiction Registered Nurse - Advanced Practice (CARN-AP) through the Addictions Nursing Certification Board.
Objectives
At the end of this training, participants will have the knowledge necessary to:
- Identify the impact of illicitly manufactured fentanyl on buprenorphine initiation and its unique challenges in treatment.
- Describe at least 2 strategies for initiating buprenorphine in individuals with opioid use disorder.
- Develop an individualized, comprehensive care plan for initiating buprenorphine in an outpatient setting.
Sponsored by
Boston Medical Center Grayken Center for Addiction TTA, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Accreditation information
Please read the Accreditation Information section of the training registration page for more information and to learn about the requirements for receiving credit or a certificate of completion.
